Hospital Universitario 12 de Octubre-ko ikertzaileekin lankidetzan egindako argitalpenak (27)

2023

  1. Characteristics and outcomes of an international cohort of 600 000 hospitalized patients with COVID-19

    International Journal of Epidemiology, Vol. 52, Núm. 2, pp. 355-376

2022

  1. ISARIC-COVID-19 dataset: A Prospective, Standardized, Global Dataset of Patients Hospitalized with COVID-19

    Scientific Data, Vol. 9, Núm. 1

  2. Optimization of levetiracetam dosing regimen in critically ill patients with augmented renal clearance: a Monte Carlo simulation study

    Journal of Intensive Care, Vol. 10, Núm. 1

2021

  1. Population pharmacokinetics of levetiracetam and dosing evaluation in critically ill patients with normal or augmented renal function

    Pharmaceutics, Vol. 13, Núm. 10

2020

  1. Impact of augmented renal clearance on the pharmacokinetics of linezolid: Advantages of continuous infusion from a pharmacokinetic/pharmacodynamic perspective

    International Journal of Infectious Diseases, Vol. 93, pp. 329-338

  2. Novel population pharmacokinetic model for linezolid in critically ill patients and evaluation of the adequacy of the current dosing recommendation

    Pharmaceutics, Vol. 12, Núm. 1

2019

  1. Pharmacokinetics of linezolid in critically ill patients on continuous renal replacement therapy: Influence of residual renal function on PK/PD target attainment

    Journal of Critical Care, Vol. 50, pp. 69-76

2016

  1. Safety management of a clinical process using failure mode and effect analysis: Continuous renal replacement therapies in intensive care unit patients

    ASAIO Journal, Vol. 62, Núm. 1, pp. 74-79

2015

  1. Optimizing the dosing regimen of linezolid in critically ill septic patients undergoing continuous hemodiafiltration using a pharmacokinetic/pharmacodynamic analysis and Monte Carlo simulation

    Intensive Care Medicine Experimental

  2. Pharmacokinetic/pharmacodynamic analysis of linezolid in critically ill patients with severe sepsis treated with renal replacement therapy

    Intensive Care Medicine Experimental

2014

  1. Population pharmacokinetics of piperacillin and tazobactam in critically ill patients undergoing continuous renal replacement therapy: Application to pharmacokinetic/pharmacodynamic analysis

    Journal of Antimicrobial Chemotherapy, Vol. 69, Núm. 1, pp. 180-189

2013

  1. Acute kidney injury in the critically Ill patient

    Critical Care Research and Practice

  2. Estimating kidney function in the critically ill patients

    Critical Care Research and Practice, Vol. 2013

  3. Hemoperfusión directa con el cartucho de polimixina b fijada en la sepsis grave secundaria a perforación intestinal: Hallazgos hemodinámicos y consideraciones clínicas con respecto a la anticoagulación

    Revista Espanola de Quimioterapia, Vol. 26, Núm. 2, pp. 151-158

  4. Prevalence of acute kidney injury in intensive care units: The "COrte de prevalencia de disFunción RenAl y DEpuración en críticos" point-prevalence multicenter study

    Journal of Critical Care, Vol. 28, Núm. 5, pp. 687-694

2012

  1. Handling continuous renal replacement therapy-related adverse effects in intensive care unit patients: The dialytrauma concept

    Blood Purification, Vol. 34, Núm. 2, pp. 177-185

  2. Mortality after surgery in Europe: A 7 day cohort study

    The Lancet, Vol. 380, Núm. 9847, pp. 1059-1065

  3. Variability in renal dysfunction defining criteria and detection methods in intensive care units: Are the international consensus criteria used for diagnosing renal dysfunction?

    Medicina Intensiva, Vol. 36, Núm. 4, pp. 264-269

2008

  1. Population pharmacokinetics of meropenem in critically ill patients undergoing continuous renal replacement therapy

    Clinical Pharmacokinetics, Vol. 47, Núm. 3, pp. 173-180

  2. To the editor

    New England Journal of Medicine